143 related articles for article (PubMed ID: 32571711)
1. Safety and Efficacy of Everolimus Rescue Treatment After Pediatric Living Donor Liver Transplantation.
Ueno T; Kodama T; Noguchi Y; Deguchi K; Nomura M; Saka R; Watanabe M; Tazuke Y; Bessho K; Okuyama H
Transplant Proc; 2020; 52(6):1829-1832. PubMed ID: 32571711
[TBL] [Abstract][Full Text] [Related]
2. Everolimus Rescue Treatment for Chronic Rejection After Pediatric Living Donor Liver Transplantation: 2 Case Reports.
Ueno T; Hiwatashi S; Saka R; Yamanaka H; Takama Y; Tazuke Y; Bessho K; Okuyama H
Transplant Proc; 2018 Nov; 50(9):2872-2876. PubMed ID: 30318104
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
Yoshimura N; Nakao T; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Ushigome H
Transplant Proc; 2016 Apr; 48(3):786-9. PubMed ID: 27234736
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
[TBL] [Abstract][Full Text] [Related]
5. Revisiting chronic rejection following living donor liver transplantation in the tacrolimus era: A single center experience.
Choudhary NS; Saraf N; Saigal S; Gautam D; Rastogi A; Goja S; Bhangui P; Srinivasan T; Yadav SK; Soin A
Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29160909
[TBL] [Abstract][Full Text] [Related]
6. Conversion from twice-daily everolimus to once-daily sirolimus in long-term stable liver transplant recipients.
Dumortier J; Boillot O
Transpl Immunol; 2024 Apr; 83():102014. PubMed ID: 38395088
[TBL] [Abstract][Full Text] [Related]
7. Serum Trough Concentration and Effects of Mycophenolate Mofetil Based on Pathologic Findings in Infants After Liver Transplantation.
Ueno T; Kodama T; Noguchi Y; Deguchi K; Nomura M; Saka R; Watanabe M; Tazuke Y; Bessho K; Okuyama H
Transplant Proc; 2020; 52(6):1855-1857. PubMed ID: 32571709
[TBL] [Abstract][Full Text] [Related]
8. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients.
Nanmoku K; Kurosawa A; Kubo T; Shinzato T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2017 Oct; 49(8):1724-1728. PubMed ID: 28923615
[TBL] [Abstract][Full Text] [Related]
9. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
10. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.
Ganschow R; Ericzon BG; Dhawan A; Sharif K; Martzloff ED; Rauer B; Ng J; Lopez P
Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28714558
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma.
Sapisochin G; Lee WC; Joo DJ; Joh JW; Hata K; Soin AS; Veldandi UK; Kaneko S; Meier M; Leclair D; Sunkara G; Jeng LB
Ann Transplant; 2022 Nov; 27():e937988. PubMed ID: 36411723
[TBL] [Abstract][Full Text] [Related]
12. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
Nogueras López F; Abellan Alfocea P; Ortega Suazo EJ; López Garrido MA; Becerra Massare A; Gila Medina AM; Redondo Cerezo E; Espinosa Aguilar MD
Transplant Proc; 2020 Mar; 52(2):556-558. PubMed ID: 32035673
[TBL] [Abstract][Full Text] [Related]
13. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
[TBL] [Abstract][Full Text] [Related]
14. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation.
Yamanaka K; Kakuta Y; Nakazawa S; Kato T; Abe T; Imamura R; Okumi M; Ichimaru N; Kyo M; Kyakuno M; Takahara S; Nonomura N
Transplant Proc; 2016 Apr; 48(3):781-5. PubMed ID: 27234735
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study.
Jeng LB; Lee SG; Soin AS; Lee WC; Suh KS; Joo DJ; Uemoto S; Joh J; Yoshizumi T; Yang HR; Song GW; Lopez P; Kochuparampil J; Sips C; Kaneko S; Levy G
Am J Transplant; 2018 Jun; 18(6):1435-1446. PubMed ID: 29237235
[TBL] [Abstract][Full Text] [Related]
16. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
[TBL] [Abstract][Full Text] [Related]
17. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
18. Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?
De Simone P; Saliba F; Dong G; Escrig C; Fischer L
Clin Transplant; 2016 Mar; 30(3):279-88. PubMed ID: 26717035
[TBL] [Abstract][Full Text] [Related]
19. Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation.
Hiramitsu T; Tomosugi T; Futamura K; Okada M; Goto N; Ichimori T; Narumi S; Watarai Y
Int Immunopharmacol; 2019 Oct; 75():105772. PubMed ID: 31376625
[TBL] [Abstract][Full Text] [Related]
20. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
